aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $334 million, is garnering attention from analysts for its innovative approach to treating fibrosis and inflammation.

SEOUL, May 21 (Reuters) - Round-up of South Korean financial markets: ** South Korean shares rose on Wednesday, as pharmaceutical stocks jumped on the government's pledge to support the sector ...

Pharmaceutical manufacturing encompasses all processes involved in the manufacturing and production of biological and medical products, botanical drugs, and herbs, as well as other pharmaceutical ...

Pfizer's US$6 billion licensing deal with 3SBio has boosted market sentiment on Chinese biotech and pharmaceutical companies, sending shares in the sector higher. 3SBio's shares surged 32% to 19. ...

Pharmaceutical maker Regeneron announced Monday it will buy genetic testing company 23andMe for $256 million following a bankruptcy auction. Regeneron said it will acquire 23andMe’s genomics ...

(AP Photo/Barbara Ortutay, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months ...

By Michael Levenson 23andMe, the genetic testing company that was once valued at $6 billion but filed for bankruptcy in March, will be bought by Regeneron Pharmaceuticals, a biotechnology company ...

More importantly to consumers who have privacy concerns during the proceedings, the pharmaceutical company promised to adhere to 23andMe's existing privacy policy, saying it will "prioritize the ...

A major pharmaceutical manufacturing company is considering planting ground in Houston, with a $5.7 billion proposed investment into a new facility. Eli Lilly applied for a tax abatement under ...

Regeneron Pharmaceuticals, a biotechnology company with a long history of large-scale genetics research, plans to buy DNA testing firm 23andMe out of bankruptcy, announcing Monday it was named the ...